We should assess the patient’s immune status (e.g., PD-1 expression levels on CD4+ and CD8+ T cells) before initiating anti-PD-1 treatment and regularly monitor immune status to provide stronger evidence for the efficacy of ICIs in treating mucormycosis. The gene discussed is CD4; the disease is Zygomycosis.